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INTRODUCTION
Ventilator-associated pneumonia (VAP) is the most common nosocomial infection in people receiving mechanical ventilation. VAP is defined as pneumonia occurring more than 48 h after endotracheal intubation/initiation of mechanical ventilation or pneumonia developing even after extubation. [1] VAP developed during the first 4 days of mechanical ventilation is early-onset, usually less severe, mostly caused by antibiotic-sensitive bacteria and with a better prognosis, whereas late-onset VAP develops five or more days after the initiation of mechanical ventilation and is due to multidrug-resistant (MDR) pathogens and is usually associated with increased morbidity and mortality. [2] VAP may be caused by a wide spectrum of bacterial pathogens, which may be polymicrobial and are rarely due to viral or fungal pathogens in immunocompetent hosts. [1] Common etiologic agents are Gram-negative b a c i l l i s u c h a s P s e u d o m o n a s aeruginosa, Escherichia coli, Klebsiella pneumoniae, and Acinetobacter spp. and Staphylococcus aureus among Gram-positive cocci. [3] Due to the increased incidence of MDR organisms in Int ensive C a re U nit s ( IC U s) , early and correct diagnosis of VAP is mandatory for optimal antibiotic therapy. [2] The frequency of specific MDR pathogens causing VAP varies in hospitals, patient populations, prior use of antibiotics and type of ICUs emphasizing the need for routine surveillance. [4] The objectives of this study were to detect the etiological agents of VAP, determine their antibiotic susceptibility pattern, to screen for the presence of β-lactamases such as extended-spectrum beta-lactamases (ESBLs), AmpC β-lactamases, carbapenemases, and metallo-beta-lactamases (MBL) and to determine the risk factors of MDR pathogens among the VAP patients.
MATERIALS AND METHODS

Study design
Study design involves observational cross-sectional study. Pulmonary Infection Score (CPIS) >6. [5] Exclusion criteria Exclusion criteria include those developed pneumonia within 48 h of mechanical ventilation.
Study site
Confirmation of ventilator-associated pneumonia diagnosis
Confirmation of VAP diagnosis involves observing >10 5 colony-forming unit (CFU)/ml by quantitative culture of endotracheal tube aspirate (ETA). [6] Demographic information collection Data such as age, gender, date of admission into ICU, duration of hospitalization, duration of mechanical ventilation, details of antibiotic therapy, history of surgery, underlying diseases, use of steroids, presence of neurological disorders, and impairment of consciousness were recorded from the medical records and bedside charts.
Specimen collection (endotracheal tube aspirates)
ETA were obtained with sterile precaution using a 22 inch, No. 14 Fr suction catheter and collected in a sterile container. A length of approximately 24 cm of the catheter was passed through the endotracheal tube, and secretions were aspirated without instilling saline. After the catheter was withdrawn, 10-fold serial dilution of ETA was done with 0.9% normal saline and then plated for quantitative culture and Gram stain.
Microbiological processing
ETA were mechanically homogenized using sterile glass beads and were centrifuged for 1 min. The samples were then serially diluted in 0.9% sterile saline solution with final dilutions of 10 −2 , 10 −3 , and 10 −4 and plated on sheep blood agar, chocolate agar, MacConkey agar and two Saboraud's dextrose agar (SDA) by using 2 mm nichrome wire loop (Hi-media, Mumbai, India), which holds 0.005 ml of solution. All plates were incubated overnight aerobically at 37°C except one SDA plate which was kept at room temperature. The plates for bacterial culture were incubated up to 48 h and SDA plates up to 1 week. For definitive diagnosis of VAP, quantitative culture threshold of >10 5 CFU/ml was considered significant. And growth of any organism below 10 5 CFU/ml was assumed to be due to colonization or contamination. [6] Any significant growth was identified based on standard microbiological techniques. [7] Antimicrobial susceptibility was performed for all the isolates with positive quantitative cultures according to Kirby Bauer's disk diffusion method. [8] For Gram-positive bacteria, vancomycin (30 µg), linezolid (30 µg), ciprofloxacin (1 µg), azithromycin (30 µg), gentamicin (5 µg), cefoxitin (30 µg), and tigecycline (15 µg) were selected. For Gram-negative bacteria, piperacillin + tazobactam (100 µg/10 µg), amikacin (5 µg), ciprofloxacin (1 µg), cefotaxime (30 µg), ceftazidime (30 µg), meropenem (10 µg), polymyxin B (300 µg), and tigecycline (15 µg) were selected. Suspected ESBL-producing organisms were confirmed by combination disk test using ceftazidime (30 µgm) and ceftazidime + clavulanic acid (30 µg/10 µg) disks. [9] Isolates that yielded a cefoxitin zone diameter of <18 mm and resistant to third-generation cephalosporins were tested for AmpC enzyme production, by the popular AmpC disk test. [10] Modified Hodge Test was carried out for the detection of carbapenemase. [11] Isolates showing resistance to carbapenems were selected for the detection of MBL enzymes by imipenem-ethylenediaminetetraacetic acid disk synergy test. [11] The Gram-negative isolates from VAP expressing ESBL, AmpC β-lactamases or MBL and Methicillin-resistant S. aureus (MRSA) among the Gram-positive isolates were considered as MDR pathogens. [2, 12] 
Statistical analysis
Data entry and analysis were done using SPSS for Windows Version SPSS 17.0 (SPSS Inc., Chicago, IL, USA). Statistical analysis was done by Chi-square with Yates correction.
RESULTS
Totally 486 patients were admitted in the MICU and CICU from October 2011 to September 2013, and 100 among them were enrolled for the study according to the inclusion criteria. Out of 100 clinically diagnosed VAP cases, 35 (35%) were confirmed by quantitative culture, of which 10 (10%) were categorized under early-onset and 25 (25%) under late-onset VAP. The infection rates were found to be more Table 3 ]. AmpC β-lactamase was detected in 6 (35.29%) and 6 (26.08%) of nonfermenters and members of Enterobacteriaceae, respectively. Nearly 21.74% (5/23) of Enterobacteriaceae were positive for ESBL. MBL were detected in both nonfermenters 3 (17.64%) and Enterobacteriaceae 4 (17.39%) [ Table 3 ]. However, ESBL production among nonfermenters was nil in our study. About 75% (3/4) of MRSA and one methicillin-resistant CONS spp. were isolated from early-onset VAP [ Table 4 ]. Prior antibiotic therapy (P = 0.000) and current hospitalization of 5 days or more (P = 0.001) were independent risk factors for VAP caused by MDR pathogens [ Table 5 ].
DISCUSSION
VAP is an important nosocomial infection among ICU patients receiving mechanical ventilation. The risk of VAP is approximately 3%/day during the first 5 days of ventilation, gradually decreasing to 2% during 5-10 days of ventilation and approximately 1%/day thereafter, thus highest during the early course of hospital stay. [13] The principal factor for the pathogenesis of VAP is reported to be due to aspiration of oropharyngeal pathogens and the leakage of secretions containing bacteria around the endotracheal tube. [14] The bacteriological approach for the management of VAP avoids the problem of over treatment by separating colonizers from infecting pathogens. [15] Quantitative cultures of endotracheal aspirate or broncho-alveolar lavage is recommended by the American Thoracic Society for confirmation of VAP. [16] Endotracheal tube aspirate is comparatively less expensive compared to BAL and hence is widely preferable in most of the hospital settings.
Investigators have also reported quantitative cultures of ETA to be of equal diagnostic accuracy to other invasive techniques. [17] VAP was confirmed by correlating positive quantitative culture results with the clinical outcome of patients. In the present study, a total of 100 clinically diagnosed VAP cases were evaluated, of which 35% were diagnosed as VAP by quantitative cultures. Age group of 41-60 years were more prone to get VAP in both males and females. Out of 35 culture positive cases, 65.71% had monomicrobial and 34.29% had polymicrobial growth. Several studies have shown up to 40% of VAP to be polymicrobial. [18] Gram-negative bacteria were isolated in 85.1%, which is well correlated with the study of Rajesh Chawla (87%) in the year 2008. [19] The microbial flora of critically ill patients in hospitals becomes drastically altered within days after admission. The nosocomial Gram-negative pathogens colonize on healthy skin of ICU people, catheters, instruments, and environments that can be even transmitted through the air. [20] Earlier reports showed, among the Gram-negative organisms, P. aeruginosa was the commonest causative agent. [1, 17] However, in the present study, Acinetobacter spp. was found to be the most common isolate (21.27%) followed by K. pneumoniae (19.15%) and Pseudomonas spp. (12.76%). The distribution of etiological agents varies in different ICUs as per patient demographics, methods of diagnosis, duration of hospitalization, ICU stays, and antibiotic policy. In the present study, Enterobacteriaceae (66.66%) were the predominant isolates from early-onset VAP followed by S. aureus (20%). Only single isolate of nonfermenter, i.e., P. aeruginosa (6.67%) was obtained from early-onset VAP. Previous studies by Dey et al. revealed Acinetobacter spp. (48.94%) as the most common isolate from early-onset VAP, in contrast to ours where no Acinetobacter spp. isolated from early-onset cases. [21] But the probable cause for this could not be explained.
Among the Gram-negative isolates, K. pneumoniae showed 100% resistance to ceftazidime, cefotaxime, and ciprofloxacin followed by meropenem (75%). Among the Gram-positive isolates from early-onset VAP, MRSA (66.66%) predominated over methicillin-susceptible S. aureus (MSSA) as reported earlier. [3] Similar to other studies, we also found all the Gram-positive isolates to be 100% sensitive to vancomycin irrespective of MRSA and MSSA. [3, 20] Late-onset VAP was associated with higher rates of infection with MDR pathogens (67.85%) [ Table 4 ]. Acinetobacter spp. (31.25%) was the predominant isolate followed by Pseudomonas spp. (15.62%) and K. pneumoniae (15.625%), which correlated well with other reports. [18] We isolated only one fungus, i.e., non-albicans Candida spp. from an elderly chronic psychiatric patient with septicemia and acute renal failure. The antibiogram of Gram-negative isolates showed highest resistance to ceftazidime (100%) followed by ciprofloxacin (89.65%), amikacin (86.21%), and piperacillin-tazobactam (62.06%). All the Acinetobacter spp. were resistant to ceftazidime, amikacin, and ciprofloxacin. Among the MDR isolates, majority were associated with risk factors such as prior antibiotic therapy (23/28) or current hospitalization for 5 days or more (27/28) [ Table 5 ]. This may be the cause for almost similar pattern of susceptibility in both late-and early-onset VAP. The American Thoracic Society guidelines have also recommended similar treatment options for both early-and late-onset VAP due to MDR pathogens. [2] Present study observed nonfermenters (69.23%) to be the predominant cause of VAP in CICU, while members of Enterobacteriaceae (58.81%) were common in the MICU followed by nonfermenters (23.52%). VAP episodes due to Gram-positive bacteria (7.69%) were relatively less common in the CICU. Knowledge regarding this difference in pathogens causing VAP in different ICU settings will definitely guide for choosing the appropriate empirical antibiotic therapy. AmpC β-lactamases, ESBLs, and MBLs were of much concern in our study. Members of Enterobacteriaceae (21.74%) were positive for ESBL only, but AmpC β-lactamase was produced by most of the nonfermenters as well as Enterobacteriaceae [ Table 3 ]. MBL was produced by most of the Acinetobacter spp. and Klebsiella spp., which differs from other studies. [18, 22, 23] Evaluation of risk factors for VAP revealed that prior antibiotic therapy (P = 0.000) and current hospitalization of 5 days or more (P = 0.001) were independent predictors of VAP caused by MDR pathogens [ Table 5 ]. Hence, the rational use of appropriate antibiotics and unnecessary prolonged hospitalization may reduce patient colonization and subsequent development of VAP with MDR pathogens. Moreover, the increasing occurrence of MDR Gram-negative bacteria is no longer responding to monotherapy and is necessitating the use of combination therapies. However, these findings may not be reflected exactly in other centers. Hence, we suggest further multicentered studies to confirm our findings. Although for the diagnosis of VAP, we did quantitative culture of ETA (>10 5 CFU/ml) and corroborated our findings with modified CPIS scoring >6, the results are yet to be compared to histology of lung tissue which is considered as the gold standard. So to conclude, quantitative culture of ETA is a practical diagnostic method to confirm clinically suspected VAP and a negative quantitative ETA culture can guide the physicians to focus their attention to extrapulmonary origin of infection.
CONCLUSION
Knowledge of the susceptibility pattern of the local pathogens can guide the clinicians to choose the appropriate antibiotics according to the likelihood of organisms of early/late-onset VAP. polymyxin B, tigecycline, and vancomycin should be used for successful targeted therapy of MDR pathogens as they showed good in vitro activity. Combined approaches of rational antibiotic therapy might be beneficial to combat high antibiotic resistance in our setup.
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